Aman Chauhan, Associate Professor at the University of California, San Francisco, shared on LinkedIn:
“It takes a village to advance cancer research – and in this case, a truly global village!
Grateful for the opportunity to present exciting new data from the Phase Ib DAREON-7 study at NANETS2026, evaluating first-line obrixtamig (DLL3-targeted T-cell engager) + standard-of-care chemotherapy in extrapulmonary neuroendocrine carcinoma (epNEC).
The results are incredibly encouraging in a disease where effective treatment options remain limited.
Key highlights:
- Overall response rate: 77.3% across all patients
- DLL3-high tumors: 87.5% response rate!
- 12-month PFS: 47% in the DLL3-high population
That last number is particularly striking. Nearly half of patients with DLL3-high tumors remained progression-free at one year on frontline – in a disease where median overall survival has historically been approximately one year.
For those of us who care for patients with epNEC, these early signals are especially meaningful and offer genuine hope for improving outcomes in this aggressive malignancy.
Excited to see this promising therapeutic strategy being evaluated in the definitive randomized Phase III DAREON-NEC-1 trial. Looking forward to seeing whether these encouraging early results translate into meaningful survival benefits in a larger, randomized population.”
Title: Outcomes with First-Line Obrixtamig plus Standard of Care in epNEC by DLL3 Expression Status: Phase Ib DAREON®-7 Study
Authors: Aman Chauhan, Saori Mishima, Ana Custodio, Emmanuel Mitry, Rocio Garcia-Carbonero, Janie Zhang, Ken Kato, Julia Koevi, Svenja Maria Palm, Zilu Liu, Valeria Lifke, Timon Vandamme, Jaume Capdevila
Read the Full Article.
You can also read: Obrixtamig Plus Ezabenlimab Shows Activity in DLL3-Positive SCLC
